Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 118

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1A
Chunk 118
---
ulatory developments or enforcement in the U.S. and other countries; 

•developments or disputes concerning patents or other proprietary rights; 

•introduction of technological innovations or new commercial products by our competitors; 

•changes in estimates or recommendations by securities analysts, if any, who cover our company; 

•public concern over our drug candidates; 

•litigation; 

•future sales of our ordinary shares by us or by existing shareholders; 

•general market conditions; 

•changes in the structure of healthcare payment systems; 

•failure of any of our drug candidates, if approved, to achieve commercial success; 

•economic and other external factors or other disasters or crises; 

•period-to-period fluctuations in our financial results; 

•overall fluctuations in U.S. equity markets; 

•our quarterly or annual results, or those of other companies in our industry; 

56

•announcements by us or our competitors of significant acquisitions or dispositions; 

•the operating and ordinary share price performance of other comparable companies; 

•investor perception of our company and the drug development industry; 

•natural or environmental disasters that investors believe may affect us; 

•changes in tax laws or regulations applicable to our business or the interpretations of those tax laws and regulations by taxing authorities; or 

•fluctuations in the budgets of federal, state and local governmental entities around the world. 

These and other external factors may cause the market price and demand for our ordinary shares to fluctuate substantially, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In particular, stock markets in general have experienced volatility that has often been unrelated to the operating performance of a particular company. These broad market fluctuations may adversely affect the trading price of our ordinary shares. Some companies that experienced volatility in the trading price of their stock have been the subject of securities class action litigation. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.

Your percentage ownership in Prothena may be diluted in the future. 

As with any publicly traded company, your percentage ownership in us may be diluted in the future because of equity issuances for acquisitions, capital raising transactions (including the sale of ordinary shares pursuant to our Amended Distribution Agreement, as may be further amended from time to time, and as discussed below), or otherwise. We may need to raise additional capital in the future. If we